T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients

NCT00057382 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

750

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: T138067 intravenous
DRUG: doxorubicin intravenous

Sponsor

Tularik